Who is sponsoring NCT01679132?

NCT01679132 is sponsored by CVRx, Inc..

What condition does NCT01679132 study?

NCT01679132 studies Uncontrolled Hypertension.

What drugs are being tested in NCT01679132?

Interventions: BAROSTIM NEO System and Medical Management.

What is the status of NCT01679132?

NCT01679132 is currently SUSPENDED.

Last reviewed 2025-07-10 · How we verify

BAROSTIM NEO Hypertension Pivotal Trial

NCT01679132 NA SUSPENDED

The purpose of this clinical investigation (NCT01679132) is to assess the long-term safety and efficacy of the BAROSTIM NEO System in subjects currently participating in the BAROSTIM Hypertension Pivotal Trial (G120137).

Details

Lead sponsor	CVRx, Inc.
Phase	NA
Status	SUSPENDED
Enrolment	10
Start date	2013-04-12
Completion	2026-03

Conditions

Uncontrolled Hypertension

Interventions

BAROSTIM NEO System and Medical Management

Primary outcomes

To assess long-term adverse events in subjects implanted with the BAROSTIM NEO System. — For the duration of the study, up to ten years.
Ascertain the type, frequency, severity and timing of long-term adverse events in G120137 study subjects implanted with the device, while providing a viable treatment option to patients currently implanted with the CVRx BAROSTIM NEO System.

Countries

United States